Table 7 The adverse events of patients with TACE-A before PSM.

From: The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus

Adverse events

All grades

III and IV grades

C-TACE-A (N/%)

D-TACE-A (N/%)

P value

C-TACE-A (N/%)

D-TACE-A (N/%)

P value

Fever

39 (50.6)

32 (60.4)

0.087

5 (6.5)

5 (9.4)

0.777

Fatigue

24 (31.2)

16 (30.2)

0.905

2 (2.6)

1 (1.9)

0.789

Pain

34 (44.2)

9 (17.0)

0.001

8 (10.4)

2 (3.8)

0.198

Nausea

21 (27.3)

16 (30.2)

0.408

3 (3.9)

1 (1.9)

0.892

Vomiting

15 (19.5)

12 (22.6)

0.662

1 (2.3)

2 (3.8)

0.567

Diarrhea

11 (14.3)

12 (22.6)

0.220

0 (0)

1 (1.9)

0.408

Hand-foot syndrome

16 (20.8)

14 (26.4)

0.454

3 (3.9)

3 (5.6)

0.687

Hypertension

25 (32.5)

20 (37.7)

0.535

5 (6.5)

4 (7.5)

0.817

Proteinuria

12 (15.6)

11 (20.8)

0.448

1 (2.3)

0 (0)

 > 0.999

Hyperbilirubinemia

5 (6.5)

5 (9.4)

0.777

0 (0)

0 (0)

 > 0.999

Back to article page